Bacterial infections are one of the most serious threats to human health, causing millions of deaths worldwide every year. However, due to the emergence of bacterial resistance, the antibacterial activity of manyRead More…
Crafting Anti-nuclear “Missile” Therapy With Antibody-drug Conjugates
In a new study, researchers from Yale School of Medicine hide tumor-fighting antibodies from cancer by disguising them in molecules that cancers use to nourish tumor growth, based on a new therapyRead More…
What’s New About Endometrial Cancer? An ADC Beyond Anticipation!
The highly anticipated 115th American Association for Cancer Research (AACR 2024) Annual Meeting opened in San Diego, USA. As the focus of the cancer research community, scientists, clinicians, and cancer researchers fromRead More…
Nature’s Breakthrough: ADCs and Base Editing Transform Blood Disease Treatment
Researchers from the University of Basel in Switzerland published a research paper titled “Selective haematological cancer eradication with preserved haematopoiesis” in the journal Nature. The entire hematopoietic system can be reconstructed byRead More…
ADCs in Cancer Therapy: Innovations, Challenges, and Outlooks
The emergence of antibody-drug conjugates (ADCs) as a potential cancer treatment pathway has attracted a great deal of attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drugRead More…
It’s High Time For Next Generation Adcs To Set Out: 5 Ways To Go – Part II
Conditionally activated antibody prodrug conjugate (PDC) Traditional ADCs not only target receptors expressed on tumor cells but also those on certain healthy tissues, leading to inevitable off-tumor toxicity. Probody Drug Conjugates (PDCs)Read More…
It’s High Time For Next Generation Adcs To Set Out: 5 Ways To Go
Antibody-drug conjugates (ADCs) represent a highly promising approach to cancer treatment, capable of selectively delivering highly cytotoxic payloads to tumors. However, ADCs are currently facing a series of challenges, including resistance, tumorRead More…
Optimization Strategies for ADC and Related Bioanalytical Methods
The emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drug molecules,Read More…
How to Screen an ADC Payload?
Introduction of the Camptothecin Derivative Payload Camptothecin was first isolated from camptothecin stems in 1966 by Wall et al., mainly in the form of topological isomerase (topoI). In order to inhibit theRead More…
Several Ways to Sort Out Sulfhydryl-Conjugated ADCs
The popularity of sulfhydryl groups in ADC preparation can be traced back to three factors: (a) thiols are the most nucleophilic amino acid side-chain functional group (much more nucleophilic than amines); (b)Read More…